|
Increases in CD4+ T Cells after IL-2 Therapy; Numbers of CD25+ CD4+ T Cells |
|||
| scIL-2 dose |
Baseline |
After 3 Cycles |
Change |
|
|
|||
| 7.5 MIU |
16.6 ± 13.0 |
315.4 ± 196.7 |
299 ± 199 |
| 1.5 MIU |
12.8 ± 13.6 |
110.6 ± 103.9 |
98 ± 111 |
| Control |
22.3 ± 15.6 |
52.3 ± 15.3 |
30 ± 23 |
|
Numbers of CD25+ CD4+ T cells at baseline and after 3 cycles of scIL-2 therapy (week 24). The high dose IL-2 produced the greatest increase in CD25 numbers after scIL-2 administration. The high group had 4, the low group has 5 and none had 3. | |||
Lewis et al. Journal of Translational Medicine 2007 5:9 doi:10.1186/1479-5876-5-9 |
|||